Please ensure Javascript is enabled for purposes of website accessibility

5-Star Stocks Poised to Pop: Pharmaceutical Product

By Brian D. Pacampara, CFA – Updated Apr 6, 2017 at 2:17AM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Market-trouncing returns could be written in these five stars.

Based on the aggregated intelligence of 130,000-plus investors participating in Motley Fool CAPS, the Fool's free investing community, contract drug research company Pharmaceutical Product Development (NASDAQ:PPDI) has earned a coveted five-star ranking.

With that in mind, let's take a closer look at PPD's business and see what CAPS investors are saying about the stock right now.

PPD facts

Headquarters (founded)

Wilmington, N.C. (1985)

Market Cap

$2.29 billion

Industry

Medical labs and research

Trailing-12-Month Revenue

$1.54 billion

Management

CEO Dr. Fredric Eshelman
CFO Daniel Darazsdi

Return on Equity (average, last three years)

16.7%

Dividend Yield

2.6%

Competitors

Covance (NYSE:CVD)
Parexel International (NASDAQ:PRXL)

CAPS members bullish on PPDI also bullish on

Johnson & Johnson (NYSE:JNJ)
General Electric (NYSE:GE)

CAPS members bearish on PPDI also bearish on

General Motors (NYSE:GM)
Morgan Stanley (NYSE:MS)

Sources: Capital IQ, a division of Standard & Poor's, and Motley Fool CAPS.

Over on CAPS, fully 440 of the 446 members who have rated PPD -- some 98.7% -- believe the stock will outperform the S&P 500 going forward. These bulls include All-Star TSIF, who is ranked in the top 5% of our community, and SmoothHughes.

Earlier this month, TSIF tapped PPD as researcher worth researching:

Decent margins, no debt, good cash flow. Somewhat recession proof in that medical companies need a continuous stream of new products to offset those losing patent protection. A full range of services that are usually farmed out by the "big boys" who don't want to keep specialized staff.

In a pitch from two weeks later, SmoothHughes concurs:

Nice balance sheet with $4/share in cash and no debt. The company has strong founding management and is in a good sector. Pharmaceuticals should have a strong tail wind with the aging baby boomers and the rapid advances in biochemistry. National medicine might even help as big pharma looks to reduce costs through more outsourcing.

What do you think about PPD, or any other stock for that matter? Make your voice heard on Motley Fool CAPS today. More than 130,000 investors are waiting to hear what you have to say. CAPS is 100% free, so simply click here to get started.

Fool contributor Brian Pacampara owns no position in any of the companies mentioned. PPD is a Motley Fool Stock Advisor pick. Johnson & Johnson is a selection of Income Investor. The Fool's disclosure policy always gets a perfect score.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Pharmaceutical Product Development, LLC Stock Quote
Pharmaceutical Product Development, LLC
PPDI
Morgan Stanley Stock Quote
Morgan Stanley
MS
$81.51 (-3.85%) $-3.26
General Electric Company Stock Quote
General Electric Company
GE
$64.55 (-1.24%) $0.81
General Motors Company Stock Quote
General Motors Company
GM
$35.48 (-5.08%) $-1.90
Johnson & Johnson Stock Quote
Johnson & Johnson
JNJ
$166.72 (0.33%) $0.54
PAREXEL International Corporation Stock Quote
PAREXEL International Corporation
PRXL

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
339%
 
S&P 500 Returns
109%

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 09/24/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.